OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Biopharmaceutical Statistics is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Introduction to the special issue Advances in statistical methods for the assessment of patient-centered outcomes	28
An adaptive seamless 2-in-1 design with biomarker-driven subgroup enrichment	22
A practical analysis procedure on generalizing comparative effectiveness in the randomized clinical trial to the real-world trial-eligible population	20
Quasi-Empirical Bayes methods for parameter estimation involving many small samples	19
Comparison of profile-likelihood-based confidence intervals with other rank-based methods for the two-sample problem in ordered categorical data	15
In vitro dissolution profile comparison using bootstrap bias corrected similarity factor, f ₂	12
Estimating treatment effect in randomized trial after control to treatment crossover using external controls	12
Different view of the diagnostics test accuracy measures and optimal cut-off point selection procedure under tree or umbrella ordering	11
scRAA: the development of a robust and automatic annotation procedure for single-cell RNA sequencing data	10
A Bayesian joint bent-cable model for longitudinal measurements and survival time with heterogeneous random-effects distributions	10
A simulation study comparing backfill and randomized expansion in oncology dose optimization	10
Estimand in benefit-risk assessment	9
A demonstration of estimands and sensitivity analyses for time-to-deterioration of patient reported outcomes	9
Statistical innovation for next generation pharmaceutical development	8
Using surrogate information to improve confirmatory platform trial with sample size re-estimation	8
Extent of safety database in pediatric drug development: types of assessment, analytical precision, and pathway for extrapolation through on-target effects	8
Optimization of EWOC principle in BLRM design for phase 1 oncology trials	8
Whole-cage randomization for animal studies with unequal cage or group sizes	8
Enhancing dose selection in phase I cancer trials: Extending the Bayesian Logistic Regression Model with non-DLT adverse events integration	8
Non-constant mean relative potency for antibody-dependent cellular cytotoxicity assays	8
Evaluating bias in the anchor method for the minimal clinically important difference: a simulation approach	7
Machine learning approach for detection of MACE events within clinical trial data	7
Directed Acyclic Graph Assisted Method For Estimating Average Treatment Effect	7
Implementation of statistical features of a Bayesian two-armed responsive adaptive randomization trial with post hoc analysis of time trend drift	7
Analysis of innovative two-stage seamless adaptive design with different endpoints and population shift	7

Case study using RWD in the context of a pivotal trial for regulatory approval in a rare disease	7
Defining optimal cut-off points for multiple class ROC analysis: generalization of the Index of Union method	7
A survey of parallelism testing methods for bioassays	7
An enriched approach to combining high-dimensional genomic and low-dimensional phenotypic data	7
Strategies for successful dose optimization in oncology drug development: a practical guide	7
PMED: Optimal Bayesian Platform Trial Design with Multiple Endpoints	6
Adjusted win ratio using the inverse probability of treatment weighting	6
MOVER tests for non-inferiority of the difference between two binary-outcome treatments in the matched-pairs design	6
Sequential monitoring of cancer immunotherapy trial with random delayed treatment effect	6
Comparison of continuous, binary, and ordinal endpoints	6
Optimal designs for phase II clinical trials with heterogeneous patient populations	6
Analysis of continuous monitoring device data	6
genRCT: a statistical analysis framework for generalizing RCT findings to real-world population	5
Guest editors’ note on special issue on application of estimand	5
Use of Bayesian decision analysis to maximize value in patient-centered randomized clinical trials in Parkinson’s disease	5
Special issue on dose optimization	5
Bayesian analysis of the causal reference-based model for missing data in clinical trials	5
Sample size determination for a study with variable follow-up time	5
Linear regression models for analyzing the covariate-adjusted Youden index and associated cut-off points in three diagnostic groups	5
FDA experiences with a centralized statistical monitoring tool	5
Bayesian screening for feature selection	5
Estimation of median survival time and its 95% confidence interval using SAS PROC LIFETEST	5
Double machine learning methods for estimating average treatment effects: a comparative study	5
Combination MCP-Mod for two-drug combination dose-ranging studies	4
Clustering plasma concentration-time curves: applications ofunsupervised learning in pharmacogenomics	4
DOD-Combo: Bayesian dose finding design in combination trials with meta-analytic-predictive prior	4
Investigating pharmacokinetic profiles of Centella asiatica using machine learning and PBPK modelling	4
Enhanced doubly robust estimation in clinical trials accounting for intercurrent events	4
Assessing the incidence and severity of drug adverse events: a Bayesian hierarchical cumulative logit model	4
Assessing the use of GEE methods for analyzing binary outcomes in family studies: the Strong Heart Family Study	4
Using Bayesian hierarchical models for controlled post hoc subgroup analysis of clinical trials: application to smoking cessation treatment in American Indians and Alaska Natives	4
Isotonic design for phase I cancer clinical trials with late-onset toxicities	4
Retrieved-Dropout-Based multiple imputation for time-to-event data in cardiovascular outcome trials	4
Bayesian method for comparing F1 scores in the absence of a gold standard	4
The impact of different data handling strategies in exploratory and confirmatory factor analysis of diary measures: an evaluation using simulated and real-world asthma nighttime symptoms diary data	4
Recovery of overall survival information from treatment switching in oncology trials using multiple imputation	4
The use of real-world data for clinical investigation of effectiveness in drug development	4
P-values and confidence intervals for weighted log-rank tests under truncated binomial design based on clustered medical data	4
Change-point detection in Weibull-accelerated failure time models via narrowest significance pursuit	4
Establishment of RWS guidance reflecting contributions of China to regulatory science	3
Random intercept hierarchical linear model for multi-regional clinical trials	3
Impacts of reducing the number of hERG assay concentration levels on IC50 estimation	3
Reflections on estimands for patient-reported outcomes in cancer clinical trials	3
Dynamic incorporation of real world evidence within the framework of adaptive design	3
Group sequential multi-arm multi-stage survival trial design with treatment selection	3
Robust time selection for interim analysis in the Bayesian phase 2 exploratory clinical trial	3
Statistical considerations for some issues in clinical bridging studies evaluating companion diagnostic devices	3
Real world data (RWD) in pediatrics	3
Guest editors’ note on the special issue International Chinese Statistical Association (ICSA) Applied Statistics Symposium 2021	3
Identifying the clinical relative importance of each correlated outcome variables in multivariate approach: an exploration using ACCORD trial data	3

Step-down multiple testing procedures for the overall population and partitioning subgroups	3
On F _β -score for medical diagnostics tests of binary diseases: proposing new measures of accuracy	3
A win ratio approach for comparing crossing survival curves in clinical trials	3
Assessment of nonlinear dose–response relationships via nonparametric regression	3
Order-of-addition in mixture and component-amount designs in orthogonal blocks	3
Common risk difference and corresponding confidence interval adjusted for multiple factors – comparison of seven different methods	3
Emerging insights and commentaries – MMRM vs LOCF	3
A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics	3
A semi-parametric approach for time-dependent ROC curves with nonignorable missing biomarker	3
Adaptive two-stage seamless sequential design for clinical trials	3
Applications of correlative analysis for chemistry, manufacturing and controls in cell and gene therapy	3
BOP2-FE: Bayesian optimal phase II design with futility and efficacy-stopping boundaries	3
Evaluating bias reduction methods in binary Emax model for reliable dose-response estimation	3
Correction	2
Generalized triple outcome decision-making in basket trials	2
Use of alternative and confirmatory data in support of rare disease drug development	2
Bayesian design of clinical trials using the scale transformed power prior	2
Novel machine learning approach to differential cell flow cytometry analysis based on projection pursuit	2
Sample size reestimation and Bayesian predictive probability for single-arm clinical trials with a time-to-event endpoint using Weibull distribution with unknown shape parameter	2
Estimation of treatment effects in early-phase randomized clinical trials involving external control data	2
A multivariate equivalence test based on Mahalanobis distance with a data-driven margin	2
Bayesian analyses of multiple random change points in survival models with applications to clinical trials	2
Estimation of treatment effects in early phase randomized clinical trials involving multiple data sources for external control	2
Comparing diagnostic tests and biomarkers based on benefit-risk under tree orderings of disease classes	2
The role of regulatory flexibility in the review and approval process of rare disease drug development	2
Using principal progression rate to quantify and compare disease progression in comparative studies	2
Use of pharmacodynamic modeling for Bayesian information borrowing in pediatric clinical trials	2
An improved biomarker-guided adaptive patient enrichment design for oncology trials	2
Addressing sequential and concurrent treatment regimens in a small n sequential, multiple assignment, randomized trial (snSMART) in the MISTIC study	2
Meta-analysis application to hERG safety evaluation in clinical trials	2
Random effect restricted mean survival time model	2
Special issue: cell and gene causal inference in the design and analysis of gene therapy clinical trials	2
Informative event rate in study determination, study design, and interim analysis monitoring with non-proportional hazards	2
On stepwise MTPs between Holm’s step-down MTP and the max- p -value MTP for co-primary endpoints: A further extension for free	2
Optimum designs for clinical trials in personalized medicine when response variance depends on treatment	2
The value of a two-armed Bayesian response adaptive randomization trial	2
Statistical considerations for using tolerance interval to set product specification for normally distributed attribute	2
Estimation of the selected treatment mean in two stage drop-the-losers design	2
Non-inferiority testing for qualitative microbiological methods:Assessing and improving the approach in USP <1223>	2
Investigating the impact of data monitoring committee recommendations on the probability of trial success	2
A basket trial design based on constrained hierarchical Bayesian model for latent subgroups	2
Developing large language models to detect adverse drug events in posts on x	2
Assessing model accuracy using random data split: a simulation study	2
Statistical methods of indirect comparison with real-world data for survival endpoint under non-proportional hazards	2
Incorporating patient-reported outcomes in dose-finding clinical trials with continuous patient enrollment	2
Response to Comment on “Emerging insights and commentaries – MMRM vs LOCF by Naitee Ting”	2
Mind the gap: Bayesian equipoise calibration of clinical trial designs	2
Robust CATE estimation using novel ensemble methods	2
An enhanced exact permutation rank-based inferential seamless phase 2/3 design	2
Addressing statistical issues when leveraging external control data in pediatric clinical trials using Bayesian dynamic borrowing	2
Reimagining optimization of clinical trials efficiency through use of statistical innovation, technology and non-standard data sources	2
A randomized Bayesian optimal phase II design with binary endpoint	2